We are live on
!
Find out more
CCM
CAAS Capital Management Portfolio holdings
AUM
$934M
1-Year Est. Return
1.45%
This Fund
S&P 500
This Quarter
Est. Return
+26.63%
1 Year Est. Return
+1.45%
3 Year Est. Return
+10.99%
5 Year Est. Return
+150.62%
10 Year Est. Return
–
AUM
$10.5B
AUM Growth
+$6.2B
(+145%)
Cap. Flow
+$4.78B
Cap. Flow
% of AUM
45.54%
Top 10 Holdings %
Top 10 Hldgs %
28.07%
Holding
985
New
521
Increased
87
Reduced
60
Closed
171
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$153M |
| 2 |
Sunrun
RUN
|
+$94.3M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$83.8M |
| 4 |
Dynatrace
DT
|
+$67.2M |
| 5 |
Consolidated Edison
ED
|
+$56.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Solar
FSLR
|
+$71.8M |
| 2 |
10x Genomics
TXG
|
+$62.3M |
| 3 |
Caesars Entertainment
CZR
|
+$60.8M |
| 4 |
Denali Therapeutics
DNLI
|
+$53.1M |
| 5 |
PENN Entertainment
PENN
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.01% |
| 2 | Healthcare | 6.25% |
| 3 | Communication Services | 2.7% |
| 4 | Consumer Discretionary | 2.07% |
| 5 | Financials | 1.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Advanced Micro Devices
AMD
$776B
| $11.8M | 0.11% |
+128,700
| New | +$11.1M |
|
|
RETA
177
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $11.8M | 0.11% |
+95,288
| New | +$12.5M |
|
|
ALXN
178
DELISTED
Alexion Pharmaceuticals
ALXN
| $11.6M | 0.11% |
+74,500
| New | +$9.57M |
|
179
CALL
General Motors
GM
$80.4B
| $11.3M | 0.11% |
272,500
+117,500
| +76% | +$4.57M |
|
180
Sprout Social
SPT
$516M
| $11.2M | 0.11% |
+246,643
| New | +$11.7M |
|
181
PUT
Bank of America
BAC
$435B
| $11.1M | 0.11% |
+366,200
| New | +$9.82M |
|
182
Leslie's
LESL
$8.9M
| $11.1M | 0.11% |
+20,000
| New | +$9M |
|
183
CALL
Walmart Inc
WMT
$885B
| $11M | 0.1% |
+228,000
| New | +$11.1M |
|
|
DRNA
184
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $10.8M | 0.1% |
+489,765
| New | +$10.8M |
|
185
CALL
Mastercard
MA
$502B
| $10.7M | 0.1% |
+29,900
| New | +$9.95M |
|
186
Adaptive Biotechnologies
ADPT
$3.59B
| $10.7M | 0.1% |
+180,431
| New | +$9.3M |
|
187
Butterfly Network
BFLY
$1.89B
| $10.6M | 0.1% |
+537,311
| New | +$6.88M |
|
188
Kymera Therapeutics
KYMR
$8.51B
| $10.5M | 0.1% |
169,771
+144,251
| +565% | +$7.04M |
|
189
CALL
Tesla
TSLA
$1.23T
| $10.5M | 0.1% |
+44,700
| New | +$7.63M |
|
190
CALL
Akamai
AKAM
$16.7B
| $10.5M | 0.1% |
100,000
| – | – |
|
191
PUT
Cisco
CSCO
$457B
| $10.4M | 0.1% |
233,500
| – | – |
|
|
ZNGA
192
CALL
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $10.4M | 0.1% |
+1,050,000
| New | +$9.45M |
|
193
PUT
Morgan Stanley
MS
$331B
| $10.3M | 0.1% |
+150,000
| New | +$8.61M |
|
194
American Well
AMWL
$180M
| $10.1M | 0.1% |
20,000
| – | – |
|
195
CALL
Zoom
ZM
$28.2B
| $10.1M | 0.1% |
30,000
| – | – |
|
196
CALL
Carnival Corporation Ltd
CCL
$38.1B
| $10.1M | 0.1% |
+466,100
| New | +$8.29M |
|
|
197
Mastercard
MA
$502B
| $10M | 0.1% |
+28,098
| New | +$9.35M |
|
198
Intuit
INTU
$86.5B
| $10M | 0.1% |
+26,398
| New | +$9.27M |
|
199
CALL
Booking.com
BKNG
$149B
| $10M | 0.1% |
112,500
| – | – |
|
200
Nkarta
NKTX
$150M
| $10M | 0.1% |
+162,905
| New | +$6.77M |
|
Similar funds
CIG
TAM
WCF
CHP
SWC
KTA
LC
SBIA
CAAS Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, CAAS Capital Management held 985 positions worth $10.5B, up 145% from $4.29B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
CAAS Capital Management deployed $4.78B of net new capital in Q4 2020, opening 521 new positions and adding to 87 existing holdings. Its largest new stake was Sunrun: 1,519,346 shares worth $105M.
By sector, the portfolio is most concentrated in Technology at 7% of assets, down from 7.8% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was First Solar, an estimated $71.8M trimmed.
- CAAS Capital Management's largest Q4 2020 buy was Sunrun: 1,519,346 shares worth $105M.
- CAAS Capital Management added most to Royalty Pharma in Q4 2020, an estimated $153M increase.
- CAAS Capital Management's biggest Q4 2020 reduction was First Solar, cutting an estimated $71.8M.
- CAAS Capital Management fully exited 10x Genomics in Q4 2020, selling an estimated $62.3M.
- CAAS Capital Management's ten largest holdings make up 28% of its $10.5B portfolio in Q4 2020.
- CAAS Capital Management opened 521 new positions and closed 171 in Q4 2020.
- CAAS Capital Management's portfolio value rose 145% quarter-over-quarter to $10.5B.
Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.